Variables | All patients (n = 80) | Unfavorable outcome (n = 39) | Favorable outcome (n = 41) | P value |
---|---|---|---|---|
Demographic features | ||||
 Male sex | 45 (56.3) | 18 (46.2) | 27 (65.9) | 0.31 |
 Age,years | 38.5 (18–79) | 44 (20–79) | 36 (18–76) | 0.31 |
Clinical features | ||||
 History of tuberculosis infection | 7 (8.8) | 5 (12.8) | 2 (4.9) | 0.26 |
 Active extra-neural tuberculosis | 41 (51.3) | 20 (51.3) | 21 (51.2) | > 0.99 |
 Immune deficiency | 15 (18.8) | 10 (25.6) | 5 (12.2) | 0.16 |
 Duration of symptoms, days | 20 (3-365) | 20 (6-365) | 20 (3-365) | 0.42 |
 Length of ICU stay, days | 12.5 (1-207) | 9 (1-207) | 15 (5-149) | 0.03 |
 Headache | 59 (73.8) | 31 (79.5) | 28 (68.3) | 0.31 |
 Irritability | 23 (28.8) | 6 (15.4) | 17 (41.5) | 0.01 |
 Nausea and vomiting | 47 (58.8) | 23 (59.0) | 24 (58.5) | > 0.99 |
 Fever (≥ 38.5℃) | 60 (75.0) | 28 (71.8) | 32 (78.0) | 0.61 |
 Neck stiffness | 67 (83.8) | 32 (82.1) | 35 (85.4) | 0.77 |
 Convulsions | 15 (18.8) | 9 (23.1) | 6 (14.6) | 0.40 |
 Focal neurological deficits | 43 (53.8) | 20 (51.3) | 23 (56.1) | 0.82 |
 Altered consciousness | 70 (87.5) | 33 (84.6) | 37 (90.2) | 0.51 |
 Lethargy | 68 (85.0) | 32 (82.1) | 36 (87.8) | 0.54 |
GCS | 3 (3–10) | 3 (3–8) | 3 (3–10) | 0.06 |
APACHE II | 23 (10–37) | 26 (12–37) | 20 (10–33) | 0.003 |
SOFA | 7 (3–13) | 7 (4–13) | 6 (3–11) | 0.03 |
Laboratory results | ||||
 Positive culture in CSF | 22 (27.8) | 13 (34.2)a | 9 (22.0) | 0.32 |
 Positive AFB in CSF | 1 (1.3) | 1 (2.8)b | 0 (0.0) | 0.47 |
 Positive PCR in CSF | 21 (26.9) | 11 (29.7)c | 10 (24.4) | 0.62 |
 CSF glucose, mmol/L | 2.32 (0.33–12.60) | 2.30 (0.33–12.60) | 2.40 (0.40-5.00) | 0.79 |
 CSF/blood glucose ratio | 0.32 (0.03–0.70) | 0.33 (0.03–0.70) | 0.30 (0.05–0.68) | 0.82 |
 CSF protein level, mg/L | 1462 (299–3816) | 1471 (299–3188) | 1453 (464–3816) | 0.31 |
 CSF leukocyte, /µl | 104 (2-1268) | 108 (4-768) | 102 (2-1268) | 0.88 |
 Peripheral blood leukocyte, /µl | 10,045 (3420–40,400) | 10,070 (3420–40,400) | 9780 (3470–26,020) | 0.36 |
 Serum sodium, mmol/L | 137 (107–158) | 137 (117–158) | 137 (107–154) | 0.67 |
Cranial CT | ||||
 Hydrocephalus | 45 (61.6) | 25 (71.4) d | 20 (52.6) e | 0.15 |
 Basal meningeal enhancement | 10 (13.7) | 5 (14.3) d | 5 (13.2) e | > 0.99 |
 Infarct | 36 (49.3) | 20 (57.1) d | 16 (42.1) e | 0.25 |
 Tuberculoma | 4 (5.5) | 3 (8.6) d | 1 (2.6) e | 0.34 |
 Pre-contrast basal hyperdensity | 6 (8.2) | 4 (11.4) d | 2 (5.3) e | 0.42 |
 Mechanical ventilation | 58 (72.5) | 37 (94.9) | 21 (51.2) | < 0.001 |
 Surgical intervention | 11 (13.8) | 7 (17.9) | 4 (9.8) | 0.34 |